EXC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Exelon Corp (EXC) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown positive financial performance and stable dividend growth, the stock is currently overbought based on technical indicators, and analysts have expressed concerns about slower growth and political/regulatory headwinds. Additionally, there are no strong proprietary trading signals or recent influential trading activity to support an immediate buy decision.
The stock is in a bullish trend with MACD above 0 and positively expanding, SMA_5 > SMA_20 > SMA_200, and a price above key resistance levels. However, RSI is at 82.018, indicating the stock is overbought. Short-term stock trend analysis suggests a potential decline in the next day (-0.41%), week (-1.17%), and month (-2.47%).
Q4 2025 adjusted EPS of $0.59 exceeded expectations.
Annual adjusted EPS for 2025 was $2.77, demonstrating consistent growth.
Dividend increased from $0.40 to $0.42 per share, reflecting stable cash flow and profitability.
Hedge funds are significantly increasing their positions in the stock (+2344.75% buying activity).
Analysts have downgraded the stock or reduced price targets, citing slower earnings growth (5%-7%) and political/regulatory challenges.
Wolfe Research downgraded the stock to Peer Perform due to valuation concerns.
KeyBanc's Underweight rating reflects limited near-term growth potential and political pressures.
Stock is overbought based on RSI and may face short-term price corrections.
Exelon reported strong financial performance in 2025/Q3 with an 8.95% YoY revenue increase, 23.76% YoY net income growth, and 22.86% YoY EPS growth. However, gross margin slightly declined by -0.58% YoY. The company also provided 2026 adjusted EPS guidance of $2.81-$2.91, showing stable growth expectations.
Analysts are mixed to cautious on Exelon. Wolfe Research downgraded the stock to Peer Perform, citing valuation and regulatory concerns. Barclays and Wells Fargo maintain Overweight ratings but have slightly reduced price targets. Morgan Stanley and RBC Capital have Neutral or Equal Weight ratings, while KeyBanc has an Underweight rating due to limited growth potential and political pressures.
